Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | CCKAR | P32238 | 3/20 | 0.35 |
| ▸ | CCKBR | P32239 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GPR6 | P46095 | 2/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6708989 | 0.91 | LMNA (0.38) | THRBCSF1RPKMLMNATRPA1 | |
| SCHEMBL6710210 | 0.90 | GSK3A (0.36) | THRBTRPA1ALDH1A1KMT2AF10 | |
| SCHEMBL6707965 | 0.90 | NTRK1 (0.35) | THRBPKMTRPA1KMT2A | |
| SCHEMBL6712448 | 0.89 | KDM4E (0.36) | LMNASMN1; SMN2ALDH1A1GPR6 | |
| SCHEMBL6712008 | 0.88 | HIF1A (0.40) | CCKARCCKBRLMNAKMT2AF10 | |
| SCHEMBL6711863 | 0.88 | GRM4 (0.37) | CCKARCCKBRLMNAKMT2AF10 | |
| SCHEMBL6710104 | 0.88 | TRPA1 (0.33) | THRBPKMLMNATRPA1KMT2A | |
| SCHEMBL6713833 | 0.87 | CXCR1 (0.34) | THRBPKMLMNATRPA1KMT2A | |
| SCHEMBL6709087 | 0.86 | TRPA1 (0.42) | LMNATRPA1KMT2AGRM4 | |
| SCHEMBL6710525 | 0.86 | PDE10A (0.34) | THRBPKMLMNATRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | THRB 4472/4885CSF1R 1430/4885PKM 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.